… , this study demonstrated that both gefitinib and erlotinib … study with inclusion of both
gefitinib and erlotinib in a properly conducted and powered phase III trial in an enriched patient …

… study analyzed experiences in treating a large population of NSCLC patients with gefitinib
and erlotinib in … We stratified all patients according to different lines of gefitinib or erlotinib. The …

… study, we demonstrated that gefitinib and erlotinib appeared to have similar outcomes in
patients … Also, in this study, patients were treated with 250mg/d of gefitinib, and there was no …

… All patients in this study were included in the analysis of AEs. Comparisons … study will be
needed to validate our results. Currently, a phase III trial of gefitinib versus erlotinib for patients …

… This study included 71 NSCLC patients who received … This study showed that erlotinib and
gefitinib had similar effectiveness but gefitinib had a better safety profile compared to erlotinib. …

… non-small cell lung cancer (NSCLC) patients in East Asia. The objective of this study was
to compare the efficacy of gefitinib and erlotinib in Taiwanese patients with advanced NSCLC. …

… of the present study was to compare the efficacy of gefitinib and erlotinib in patients with …
Pulmonary adenocarcinoma patients who began receiving gefitinib or erlotinib treatment …

… The present study identified no significant differences in efficacy or toxicity profile between
first-line erlotinib and gefitinib for patients with EGFR-mutant disease, and these results could …

8041 Background: Second-line therapy for advanced LA pts after progression on platinum-based
regimens typically employs chemotherapy (CT) or EGFR-TKIs. Both G and E improved …

… Afatinib and gefitinib have also demonstrated efficacy in the first-line treatment of … erlotinib
patients could crossover to receive GP and GP patients could crossover to receive erlotinib. All …